E2F1 (Transcription factor E2F1) variants and mutations
E2F1 (also known as Transcription factor E2F1) is a human protein-coding gene encoding a transcription factor protein. It activates genes required for DNA replication and cell-cycle progression but can also promote apoptosis after severe stress. Dysregulated E2F1 activity is common downstream of RB-pathway disruption in cancer and contributes to uncontrolled proliferation. This analysis covers 731 E2F1 variants and mutations. Of these, 84% have computational variant effect predictions. Disease context includes benign prostatic hyperplasia, neurodegenerative disease, and Alzheimer disease. Example E2F1 variants include A2T, G5R, and A6S.
Variant analysis overview
- Gene: E2F1
- Protein: Transcription factor E2F1
- UniProt accession: Q01094
- Organism: Homo sapiens
- Variants analyzed: 731
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 421 unspecified-consequence records; 1 stop retained variant; 1 stop lost; 112 synonymous variants; 160 missense variants; 8 frameshift variants; 10 stop-gained variants; 9 in-frame deletions; 4 splice-region variants; 1 in-frame insertions; 4 substitution
- Prediction scores: 617 variants have prediction scores (84% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: benign prostatic hyperplasia, neurodegenerative disease, Alzheimer disease, Parkinson disease, multiple sclerosis, lysosomal storage disease, skin neoplasm, exocrine pancreatic carcinoma, Familial prostate cancer, prostate cancer, hepatocellular carcinoma, melanoma.
Protein structure and variant hotspots
- Protein features: 8 post-translational modification sites.
- PTM context: 17 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable E2F1 variants
Examples include A2T, G5R, A6S, P7S, A8E, A8V, G9D, G9S. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- A2T (p.Ala2Thr), Ensembl rs2122555202, REVEL 0.08, CADD 23.90
- G5R (p.Gly5Arg), gnomAD rs1329261524, REVEL 0.04, CADD 22.20, Uncertain significance, not specified
- A6S (p.Ala6Ser), TOPMed rs1467155271, gnomAD rs1467155271, REVEL 0.04, CADD 17.30
- P7S (p.Pro7Ser), TOPMed rs1463146837, gnomAD rs1463146837, REVEL 0.04, CADD 16.50
- A8E (p.Ala8Glu), 1000Genomes rs974575261, TOPMed rs974575261, gnomAD rs974575261, REVEL 0.04, CADD 18.80
- A8V (p.Ala8Val), 1000Genomes rs974575261, TOPMed rs974575261, gnomAD rs974575261, REVEL 0.04, CADD 18.80
- G9D (p.Gly9Asp), TOPMed rs1397093511, gnomAD rs1397093511, REVEL 0.07, CADD 23.40
- G9S (p.Gly9Ser), TOPMed rs2018068719, REVEL 0.04, CADD 18.90
- G10C (p.Gly10Cys), TOPMed rs1892015588, REVEL 0.04, CADD 22.60
- P11A (p.Pro11Ala), TOPMed rs1336775242, REVEL 0.02, CADD 13.90
- P11T (p.Pro11Thr), TOPMed rs1336775242, REVEL 0.02, CADD 14.50
- C12R (p.Cys12Arg), 1000Genomes rs574523664, ExAC rs574523664, TOPMed rs574523664, gnomAD rs574523664, REVEL 0.03, CADD 15.80, Benign
- C12S (p.Cys12Ser), rs574523664, ClinGen CA9818818, ClinVar RCV000904208, 1000Genomes rs574523664, REVEL 0.01, CADD 10.70, Benign, not provided
- C12Y (p.Cys12Tyr), TOPMed rs2018068494, REVEL 0.02, CADD 13.50
- A13P (p.Ala13Pro), TOPMed rs2018068417, gnomAD rs2018068417, REVEL 0.05, CADD 17.10
- A15T (p.Ala15Thr), Ensembl rs1640052920, REVEL 0.08, CADD 16.50
- A15V (p.Ala15Val), gnomAD rs1281052952, REVEL 0.09, CADD 14.00
- L16P (p.Leu16Pro), Ensembl rs2018068291, REVEL 0.11, CADD 17.30
- E17* (p.Glu17Ter), NCI-TCGA TCGA novel, CADD 34.00, Variant assessed as somatic; high impact.
- E17V (p.Glu17Val), gnomAD rs1185589452, REVEL 0.03, CADD 19.90
- L20F (p.Leu20Phe), Ensembl rs2018068184, REVEL 0.02, CADD 14.50
- G21R (p.Gly21Arg), rs1019744956, ClinGen CA313290970, ClinVar RCV004104236, TOPMed rs1019744956, REVEL 0.05, CADD 20.10, Uncertain significance, not specified
- G23D (p.Gly23Asp), gnomAD rs1367513756, REVEL 0.04, CADD 9.13
- G23S (p.Gly23Ser), TOPMed rs1405640419, gnomAD rs1405640419, REVEL 0.03, CADD 15.50, Uncertain significance, not specified
- A24T (p.Ala24Thr), gnomAD rs1237692050, REVEL 0.08, CADD 9.56
- L25P (p.Leu25Pro), gnomAD rs1405256181, REVEL 0.16, CADD 11.20
- R26Q (p.Arg26Gln), Ensembl rs1429570307, REVEL 0.08, CADD 8.93
- R26W (p.Arg26Trp), TOPMed rs1386191320, gnomAD rs1386191320, REVEL 0.12, CADD 21.40
- L28F (p.Leu28Phe), rs1160676980, gnomAD rs1160676980, REVEL 0.05, CADD 22.10, Variant assessed as somatic; moderate impact.
- D29E (p.Asp29Glu), TOPMed rs1008300493, REVEL 0.03, CADD 8.84
- S31* (p.Ser31Ter), gnomAD rs1452027367, CADD 34.00
- Q32E (p.Gln32Glu), TOPMed rs2018067572, REVEL 0.08, CADD 23.00
- V34L (p.Val34Leu), TOPMed rs1456437519, REVEL 0.04, CADD 15.50
- I35L (p.Ile35Leu), TOPMed rs1300481628, gnomAD rs1300481628, REVEL 0.01, CADD 20.30, Uncertain significance, not specified
- I35V (p.Ile35Val), TOPMed rs1300481628, gnomAD rs1300481628, REVEL 0.03, CADD 18.00
- A39T (p.Ala39Thr), TOPMed rs2018067364, REVEL 0.09, CADD 13.90
- Q40H (p.Gln40His), gnomAD rs2018067335, REVEL 0.07, CADD 13.10
- D41N (p.Asp41Asn), TOPMed rs2018067306, REVEL 0.16, CADD 14.50
- A42G (p.Ala42Gly), Ensembl rs2122554898, REVEL 0.09, CADD 14.60
- A42S (p.Ala42Ser), Ensembl rs2018067277, REVEL 0.05, CADD 12.40
- S43R (p.Ser43Arg), TOPMed rs1011962033, gnomAD rs1011962033, REVEL 0.01, CADD 14.00
- A44D (p.Ala44Asp), Ensembl rs2018067148, REVEL 0.04, CADD 11.60
- P45S (p.Pro45Ser), gnomAD rs1209626586, REVEL 0.10, CADD 13.10
- P48S (p.Pro48Ser), TOPMed rs1354620926, gnomAD rs1354620926, REVEL 0.03, CADD 15.00
- T49A (p.Thr49Ala), Ensembl rs2018066953, REVEL 0.00, CADD 1.72
- P51S (p.Pro51Ser), gnomAD rs2018066836, REVEL 0.03, CADD 12.60
- P51T (p.Pro51Thr), gnomAD rs2018066836, REVEL 0.03, CADD 12.10
- A52S (p.Ala52Ser), TOPMed rs1320649718, gnomAD rs1320649718, REVEL 0.01, CADD 8.27
- A52T (p.Ala52Thr), NCI-TCGA TCGA novel, REVEL 0.02, CADD 10.60, Variant assessed as somatic; moderate impact.
- A53T (p.Ala53Thr), TOPMed rs1218731737, gnomAD rs1218731737, REVEL 0.03, CADD 12.60
- A53V (p.Ala53Val), TOPMed rs2018066720, gnomAD rs2018066720, REVEL 0.01, CADD 7.89, Uncertain significance, not specified
- P54A (p.Pro54Ala), Ensembl rs1601190058, REVEL 0.06, CADD 6.47
- P54L (p.Pro54Leu), TOPMed rs1252483725, gnomAD rs1252483725, REVEL 0.01, CADD 12.00
- A55S (p.Ala55Ser), gnomAD rs13041707, REVEL 0.01, CADD 4.58
- A56G (p.Ala56Gly), gnomAD rs2018066424
- A56S (p.Ala56Ser), Ensembl rs13041706, REVEL 0.01, CADD 2.14
- A56T (p.Ala56Thr), Ensembl rs13041706, REVEL 0.02, CADD 5.03
- A56V (p.Ala56Val), gnomAD rs2018066424, REVEL 0.03, CADD 12.40
- G57D (p.Gly57Asp), 1000Genomes rs2122554773, REVEL 0.07, CADD 13.50
- G57R (p.Gly57Arg), 1000Genomes rs2122554775, REVEL 0.04, CADD 16.60
- P58L (p.Pro58Leu), TOPMed rs1249387152, gnomAD rs1249387152, REVEL 0.06, CADD 14.40
- P58S (p.Pro58Ser), 1000Genomes rs1045481159, TOPMed rs1045481159, gnomAD rs1045481159, REVEL 0.02, CADD 4.67, Uncertain significance, not specified
- D60N (p.Asp60Asn), TOPMed rs2018066324, REVEL 0.04, CADD 15.40
- D60Y (p.Asp60Tyr), TOPMed rs2018066324, REVEL 0.05, CADD 19.30
- P61R (p.Pro61Arg), rs2515398714, ClinGen CA408655165, ClinVar RCV004382110, Uncertain significance, not specified
- L63R (p.Leu63Arg), gnomAD rs2018066194, REVEL 0.07, CADD 22.50
- L65F (p.Leu65Phe), Ensembl rs940463871, REVEL 0.09, CADD 23.60
- A67P (p.Ala67Pro), rs2515398681, ClinGen CA408655131, ClinVar RCV004298861, REVEL 0.10, CADD 24.00, Uncertain significance, not specified
- P72L (p.Pro72Leu), TOPMed rs2018065961
- R73Q (p.Arg73Gln), gnomAD rs2018065906, REVEL 0.13, CADD 17.30
- R73W (p.Arg73Trp), TOPMed rs2018065942, REVEL 0.13, CADD 23.30
- P74R (p.Pro74Arg), TOPMed rs2018065814
- P74S (p.Pro74Ser), Ensembl rs2018065845, REVEL 0.05, CADD 13.80
- P76R (p.Pro76Arg), TOPMed rs1163948608, gnomAD rs1163948608, REVEL 0.02, CADD 13.10
- P76S (p.Pro76Ser), rs907590073, ClinGen CA313290931, ClinVar RCV004172818, TOPMed rs907590073, REVEL 0.03, CADD 10.30, Uncertain significance, not specified
- S77G (p.Ser77Gly), TOPMed rs1429701584, gnomAD rs1429701584, REVEL 0.08, CADD 16.60
- S77R (p.Ser77Arg), rs2515398621, ClinGen CA408655064, ClinVar RCV004382111, REVEL 0.05, CADD 15.10, Uncertain significance, not specified
- A78S (p.Ala78Ser), rs1306675586, ClinGen CA408655059, ClinVar RCV004314932, TOPMed rs1306675586, REVEL 0.02, CADD 9.92, Uncertain significance, not specified
- A78V (p.Ala78Val), Ensembl rs1601190008, REVEL 0.09, CADD 12.10
- R80Q (p.Arg80Gln), TOPMed rs1415762835, gnomAD rs1415762835, REVEL 0.08, CADD 17.90
- P81L (p.Pro81Leu), Ensembl rs2018065275
- A82E (p.Ala82Glu), Ensembl rs1226199249
- A82S (p.Ala82Ser), NCI-TCGA TCGA novel, REVEL 0.01, CADD 14.40, Variant assessed as somatic; moderate impact.
- A82T (p.Ala82Thr), TOPMed rs930265454, gnomAD rs930265454, REVEL 0.01, CADD 16.20
- L83F (p.Leu83Phe), TOPMed rs1297124529, REVEL 0.04, CADD 22.90
- G84S (p.Gly84Ser), TOPMed rs1307523848, gnomAD rs1307523848, REVEL 0.05, CADD 22.80
- P87R (p.Pro87Arg), gnomAD rs1447539203, REVEL 0.10, CADD 28.40
- P87S (p.Pro87Ser), TOPMed rs2018064922, REVEL 0.07, CADD 26.80, Uncertain significance, not specified
- P87T (p.Pro87Thr), TOPMed rs2018064922, REVEL 0.09, CADD 25.20
- K89R (p.Lys89Arg), ExAC rs757413708, gnomAD rs757413708
- R90W (p.Arg90Trp), NCI-TCGA Cosmic COSV5853, TOPMed rs2018006865, REVEL 0.21, CADD 28.80, Variant assessed as somatic; moderate impact.
- D93E (p.Asp93Glu), 1000Genomes rs560305222, ExAC rs560305222, TOPMed rs560305222, gnomAD rs560305222, REVEL 0.09, CADD 22.40
- D93N (p.Asp93Asn), TOPMed rs1445293021
- T96A (p.Thr96Ala), TOPMed rs2018006749
- D97H (p.Asp97His), ExAC rs758760049, gnomAD rs758760049, REVEL 0.16, CADD 25.90
- H98Y (p.His98Tyr), NCI-TCGA Cosmic COSV5853, Variant assessed as somatic; moderate impact.
- Q99* (p.Gln99Ter), NCI-TCGA Cosmic COSV1005, Variant assessed as somatic; high impact.
- Q99R (p.Gln99Arg), TOPMed rs2018006679
- Y100C (p.Tyr100Cys), ExAC rs753190783, gnomAD rs753190783, REVEL 0.14, CADD 27.40
- Y100F (p.Tyr100Phe), ExAC rs753190783, gnomAD rs753190783, REVEL 0.14, CADD 24.00
- L101P (p.Leu101Pro), TOPMed rs1434158366, gnomAD rs1434158366, REVEL 0.07, CADD 25.90
- A102T (p.Ala102Thr), rs145741678, ClinGen CA9818795, ClinVar RCV000967798, ClinVar RCV003936053, REVEL 0.08, CADD 22.10, Likely benign, not provided
- E103D (p.Glu103Asp), 1000Genomes rs577941795, ExAC rs577941795, gnomAD rs577941795, REVEL 0.04, CADD 14.20
- E103K (p.Glu103Lys), ExAC rs747305116, TOPMed rs747305116, gnomAD rs747305116, REVEL 0.10, CADD 23.60, Uncertain significance, not specified
- P107R (p.Pro107Arg), ExAC rs767288307, gnomAD rs767288307
- A108D (p.Ala108Asp), TOPMed rs1159129500, gnomAD rs1159129500, REVEL 0.04, CADD 13.50
- A108V (p.Ala108Val), TOPMed rs1159129500, gnomAD rs1159129500, REVEL 0.07, CADD 13.30
- R109P (p.Arg109Pro), 1000Genomes rs199740633, TOPMed rs199740633, gnomAD rs199740633, REVEL 0.12, CADD 23.70
- R109Q (p.Arg109Gln), 1000Genomes rs199740633, TOPMed rs199740633, gnomAD rs199740633, REVEL 0.06, CADD 24.90
- R109W (p.Arg109Trp), ESP rs149803612, ExAC rs149803612, TOPMed rs149803612, gnomAD rs149803612, REVEL 0.04, CADD 23.90
- G110S (p.Gly110Ser), NCI-TCGA Cosmic COSV5853, Variant assessed as somatic; moderate impact.
- R113C (p.Arg113Cys), ExAC rs774045899, TOPMed rs774045899, gnomAD rs774045899, REVEL 0.13, CADD 28.80
- R113H (p.Arg113His), ExAC rs768373441, TOPMed rs768373441, gnomAD rs768373441, REVEL 0.09, CADD 25.80
- P115T (p.Pro115Thr), TOPMed rs1439667088
- G118C (p.Gly118Cys), TOPMed rs2018006137
- S121Y (p.Ser121Tyr), Ensembl rs2018003363, REVEL 0.26, CADD 27.10, Uncertain significance, not specified
- P122L (p.Pro122Leu), 1000Genomes rs200324089, ExAC rs200324089, TOPMed rs200324089, gnomAD rs200324089, REVEL 0.17, CADD 24.50
- P122Q (p.Pro122Gln), 1000Genomes rs200324089, ExAC rs200324089, TOPMed rs200324089, gnomAD rs200324089, REVEL 0.23, CADD 27.60
- E124G (p.Glu124Gly), ExAC rs748471303, gnomAD rs748471303, REVEL 0.28, CADD 32.00
- E124Q (p.Glu124Gln), NCI-TCGA Cosmic COSV1005, Variant assessed as somatic; moderate impact.
- E124R (p.Glu124Arg), NCI-TCGA Cosmic COSV1005, Variant assessed as somatic; high impact.
- S126L (p.Ser126Leu), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- R127C (p.Arg127Cys), NCI-TCGA TCGA novel, REVEL 0.55, CADD 32.00, Variant assessed as somatic; moderate impact.
- R127H (p.Arg127His), NCI-TCGA Cosmic COSV1005, NCI-TCGA Cosmic COSV5853, REVEL 0.65, CADD 28.40, Variant assessed as somatic; moderate impact.
- Y128F (p.Tyr128Phe), TOPMed rs1349182634, gnomAD rs1349182634, REVEL 0.35, CADD 27.40
- E129* (p.Glu129Ter), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- E129G (p.Glu129Gly), Ensembl rs2018003103
- T130S (p.Thr130Ser), ExAC rs779392416, gnomAD rs779392416, REVEL 0.36, CADD 26.50
- S131* (p.Ser131Ter), NCI-TCGA Cosmic COSV5853, Variant assessed as somatic; high impact.
- S131L (p.Ser131Leu), NCI-TCGA Cosmic COSV5853, Variant assessed as somatic; moderate impact.
- N133S (p.Asn133Ser), TOPMed rs1485295370, gnomAD rs1485295370, REVEL 0.19, CADD 23.30
- T135I (p.Thr135Ile), ExAC rs755388533, gnomAD rs755388533, REVEL 0.23, CADD 23.60
- T135P (p.Thr135Pro), Ensembl rs1601186675
- R138C (p.Arg138Cys), NCI-TCGA Cosmic COSV5853, REVEL 0.44, CADD 29.60, Variant assessed as somatic; moderate impact.
- R138H (p.Arg138His), gnomAD rs2018002858, REVEL 0.34, CADD 26.40
- E141G (p.Glu141Gly), Ensembl rs2018002835, Uncertain significance, not specified
- S144R (p.Ser144Arg), NCI-TCGA Cosmic COSV5853, Variant assessed as somatic; moderate impact.
- H145R (p.His145Arg), Ensembl rs2018002713
- H145Y (p.His145Tyr), NCI-TCGA TCGA novel, TOPMed rs2018002735, gnomAD rs2018002735, REVEL 0.07, CADD 21.70, Variant assessed as somatic; moderate impact.
- S146L (p.Ser146Leu), NCI-TCGA TCGA novel, REVEL 0.57, CADD 26.00, Variant assessed as somatic; moderate impact.
- A147V (p.Ala147Val), ExAC rs751015434, TOPMed rs751015434, gnomAD rs751015434, REVEL 0.20, CADD 24.30
- D148N (p.Asp148Asn), NCI-TCGA Cosmic COSV5853, Variant assessed as somatic; moderate impact.
- D148V (p.Asp148Val), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- V151A (p.Val151Ala), ExAC rs752291306, gnomAD rs752291306
- V151D (p.Val151Asp), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- V151I (p.Val151Ile), ExAC rs758127423, gnomAD rs758127423, REVEL 0.25, CADD 23.10
- V151L (p.Val151Leu), NCI-TCGA Cosmic COSV5853, Variant assessed as somatic; moderate impact.
- D152N (p.Asp152Asn), Ensembl rs2122546179, REVEL 0.43, CADD 25.20
- E158K (p.Glu158Lys), ExAC rs759306871, gnomAD rs759306871, REVEL 0.14, CADD 24.60
- V159A (p.Val159Ala), Ensembl rs2018002314
- V159M (p.Val159Met), ESP rs371120550, ExAC rs371120550, TOPMed rs371120550, gnomAD rs371120550, REVEL 0.20, CADD 24.40
- V162A (p.Val162Ala), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- Q163R (p.Gln163Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- R165Q (p.Arg165Gln), NCI-TCGA Cosmic COSV5853, REVEL 0.78, CADD 25.80, Variant assessed as somatic; moderate impact.
- R165W (p.Arg165Trp), NCI-TCGA Cosmic COSV5853, Ensembl rs2122546139, Variant assessed as somatic; moderate impact.
- R166H (p.Arg166His), rs864622017, ClinGen CA348785, NCI-TCGA Cosmic COSV5853, ClinVar RCV000204567, REVEL 0.76, CADD 26.50, Uncertain significance, Prostate cancer
- I167V (p.Ile167Val), TOPMed rs1601186617
- Y168C (p.Tyr168Cys), NCI-TCGA Cosmic COSV5853, Ensembl rs1762881056, Variant assessed as somatic; moderate impact.
- N172S (p.Asn172Ser), TOPMed rs1413440731
- L174I (p.Leu174Ile), NCI-TCGA Cosmic COSV1005, NCI-TCGA Cosmic COSV5853, Variant assessed as somatic; moderate impact.
- L179F (p.Leu179Phe), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- I180V (p.Ile180Val), ESP rs377425346, ExAC rs377425346, gnomAD rs377425346, REVEL 0.23, CADD 25.50
- K185E (p.Lys185Glu), NCI-TCGA TCGA novel, Variant assessed as somatic; high impact.
- Q189* (p.Gln189Ter), NCI-TCGA Cosmic COSV5853, Variant assessed as somatic; high impact.
- G192A (p.Gly192Ala), ExAC rs776055929, gnomAD rs776055929, REVEL 0.41, CADD 23.90
- S193R (p.Ser193Arg), TOPMed rs1315185562, gnomAD rs1315185562, REVEL 0.05, CADD 13.80, Uncertain significance, not specified
- H194Y (p.His194Tyr), ExAC rs770049550, gnomAD rs770049550, REVEL 0.06, CADD 18.90
- T195P (p.Thr195Pro), Ensembl rs2122544183
- T196I (p.Thr196Ile), TOPMed rs1862522190, REVEL 0.04, CADD 10.10
- V197A (p.Val197Ala), Ensembl rs2017985125, REVEL 0.06, CADD 13.10
- V199A (p.Val199Ala), NCI-TCGA Cosmic COSV9986, Variant assessed as somatic; moderate impact.
- V199F (p.Val199Phe), ExAC rs771638059, TOPMed rs771638059, gnomAD rs771638059
- V199I (p.Val199Ile), ExAC rs771638059, TOPMed rs771638059, gnomAD rs771638059, REVEL 0.02, CADD 0.43
- G200D (p.Gly200Asp), ExAC rs754564586, gnomAD rs754564586, REVEL 0.11, CADD 9.77
- G200S (p.Gly200Ser), rs35385772, ClinGen CA9818714, ClinVar RCV003929794, UniProt VAR 048907, REVEL 0.02, CADD 0.06, Benign, E2F1-related disorder
- G201R (p.Gly201Arg), ExAC rs753472103, TOPMed rs753472103, gnomAD rs753472103, REVEL 0.06, CADD 8.61
- R202Q (p.Arg202Gln), ESP rs373902244, ExAC rs373902244, TOPMed rs373902244, gnomAD rs373902244, REVEL 0.15, CADD 8.68
- R202W (p.Arg202Trp), rs377637237, ESP rs377637237, ExAC rs377637237, TOPMed rs377637237, REVEL 0.35, CADD 23.20, Variant assessed as somatic; moderate impact.
- L203H (p.Leu203His), 1000Genomes rs546049774, gnomAD rs546049774, REVEL 0.31, CADD 16.20
- G205E (p.Gly205Glu), ExAC rs750422437, gnomAD rs750422437, REVEL 0.07, CADD 10.60
Public E2F1 analysis runs
- E2F1 analysis run — E2F1 (731 variants) — completed 2026-08-19